BackgroundPharmacogenetics (PGx) may support more individualized pediatric therapy by accounting for genetic variability in drug response, toxicity, and dose requirements. However, the extent and manner in which pharmacogenetic and biomarker-related components are incorporated into pediatric clinical trials remain incompletely characterized.ObjectivesTo qualitatively examine how pharmacogenetic and biomarker-related components are represented and operationalized in pediatric clinical trials regi